» Articles » PMID: 24871342

Many Approved Drugs Have Bioactive Analogs with Different Target Annotations

Overview
Journal AAPS J
Specialty Pharmacology
Date 2014 May 30
PMID 24871342
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Close structural relationships between approved drugs and bioactive compounds were systematically assessed using matched molecular pairs. For structural analogs of drugs, target information was assembled from ChEMBL and compared to drug targets reported in DrugBank. For many drugs, multiple analogs were identified that were active against different targets. Some of these additional targets were closely related to known drug targets while others were not. Surprising discrepancies between reported drug targets and targets of close structural analogs were often observed. On one hand, the results suggest that hypotheses concerning alternative drug targets can often be formulated on the basis of close structural relationships to bioactive compounds that are easily detectable. It is conceivable that such obvious structure-target relationships are frequently not considered (or might be overlooked) when compounds are developed with a focus on a primary target and a few related (or undesired) ones. On the other hand, our findings also raise questions concerning database content and drug repositioning efforts.

Citing Articles

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD.

Zhu Y, Xu S, Lu Y, Wei Y, Yao B, Guo F Front Pharmacol. 2020; 11:590.

PMID: 32477115 PMC: 7240069. DOI: 10.3389/fphar.2020.00590.


ChEMBL: towards direct deposition of bioassay data.

Mendez D, Gaulton A, Bento A, Chambers J, de Veij M, Felix E Nucleic Acids Res. 2018; 47(D1):D930-D940.

PMID: 30398643 PMC: 6323927. DOI: 10.1093/nar/gky1075.


Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens.

Kunimoto R, Dimova D, Bajorath J ACS Omega. 2018; 2(4):1463-1468.

PMID: 30023635 PMC: 6044569. DOI: 10.1021/acsomega.7b00215.


Design of a tripartite network for the prediction of drug targets.

Kunimoto R, Bajorath J J Comput Aided Mol Des. 2018; 32(2):321-330.

PMID: 29340865 DOI: 10.1007/s10822-018-0098-x.


Using ChEMBL web services for building applications and data processing workflows relevant to drug discovery.

Nowotka M, Gaulton A, Mendez D, Bento A, Hersey A, Leach A Expert Opin Drug Discov. 2017; 12(8):757-767.

PMID: 28602100 PMC: 6321761. DOI: 10.1080/17460441.2017.1339032.


References
1.
Hu Y, Bajorath J . Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs. ChemMedChem. 2009; 5(2):187-90. DOI: 10.1002/cmdc.200900419. View

2.
Muraoka S, Miura T . Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003; 92(2):100-4. DOI: 10.1034/j.1600-0773.2003.920207.x. View

3.
Campillos M, Kuhn M, Gavin A, Jensen L, Bork P . Drug target identification using side-effect similarity. Science. 2008; 321(5886):263-6. DOI: 10.1126/science.1158140. View

4.
Sebban C, Millan M, Spedding M . Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil. Br J Pharmacol. 1999; 128(5):1055-63. PMC: 1571732. DOI: 10.1038/sj.bjp.0702893. View

5.
Mignot E, Nishino S, Guilleminault C, Dement W . Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994; 17(5):436-7. DOI: 10.1093/sleep/17.5.436. View